Oral etoposide as first‐line therapy in the treatment of patients with advanced classic Kaposi’s sarcoma (CKS): a single‐arm trial (oral etoposide in CKS)
Identifieur interne : 000C45 ( Istex/Corpus ); précédent : 000C44; suivant : 000C46Oral etoposide as first‐line therapy in the treatment of patients with advanced classic Kaposi’s sarcoma (CKS): a single‐arm trial (oral etoposide in CKS)
Auteurs : F. Tas ; F. Sen ; S. Keskin ; L. KilicSource :
- Journal of the European Academy of Dermatology and Venereology [ 0926-9959 ] ; 2013-06.
Abstract
Background Classic Kaposi’s sarcoma (CKS) affects an elderly population; it is important to have effective treatment options with high activity and relatively low toxicity, and availability to be used for long periods.
Url:
DOI: 10.1111/j.1468-3083.2011.04404.x
Links to Exploration step
ISTEX:1AAFF4322434DC1B2D465784F08912917BE752C3Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Oral etoposide as first‐line therapy in the treatment of patients with advanced classic Kaposi’s sarcoma (CKS): a single‐arm trial (oral etoposide in CKS)</title><author><name sortKey="Tas, F" sort="Tas, F" uniqKey="Tas F" first="F." last="Tas">F. Tas</name><affiliation><mods:affiliation>E-mail: faruktas2002@yahoo.com</mods:affiliation></affiliation></author><author><name sortKey="Sen, F" sort="Sen, F" uniqKey="Sen F" first="F." last="Sen">F. Sen</name><affiliation><mods:affiliation>Institute of Oncology, University of Istanbul, Istanbul, Turkey</mods:affiliation></affiliation></author><author><name sortKey="Keskin, S" sort="Keskin, S" uniqKey="Keskin S" first="S." last="Keskin">S. Keskin</name><affiliation><mods:affiliation>Institute of Oncology, University of Istanbul, Istanbul, Turkey</mods:affiliation></affiliation></author><author><name sortKey="Kilic, L" sort="Kilic, L" uniqKey="Kilic L" first="L." last="Kilic">L. Kilic</name><affiliation><mods:affiliation>Institute of Oncology, University of Istanbul, Istanbul, Turkey</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1AAFF4322434DC1B2D465784F08912917BE752C3</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1111/j.1468-3083.2011.04404.x</idno><idno type="url">https://api.istex.fr/document/1AAFF4322434DC1B2D465784F08912917BE752C3/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000C45</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000C45</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Oral etoposide as first‐line therapy in the treatment of patients with advanced classic Kaposi’s sarcoma (CKS): a single‐arm trial (oral etoposide in CKS)</title><author><name sortKey="Tas, F" sort="Tas, F" uniqKey="Tas F" first="F." last="Tas">F. Tas</name><affiliation><mods:affiliation>E-mail: faruktas2002@yahoo.com</mods:affiliation></affiliation></author><author><name sortKey="Sen, F" sort="Sen, F" uniqKey="Sen F" first="F." last="Sen">F. Sen</name><affiliation><mods:affiliation>Institute of Oncology, University of Istanbul, Istanbul, Turkey</mods:affiliation></affiliation></author><author><name sortKey="Keskin, S" sort="Keskin, S" uniqKey="Keskin S" first="S." last="Keskin">S. Keskin</name><affiliation><mods:affiliation>Institute of Oncology, University of Istanbul, Istanbul, Turkey</mods:affiliation></affiliation></author><author><name sortKey="Kilic, L" sort="Kilic, L" uniqKey="Kilic L" first="L." last="Kilic">L. Kilic</name><affiliation><mods:affiliation>Institute of Oncology, University of Istanbul, Istanbul, Turkey</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Journal of the European Academy of Dermatology and Venereology</title><title level="j" type="alt">JOURNAL OF EUROPEAN ACADEMY DERMATOLOGY VENEREOLOGY</title><idno type="ISSN">0926-9959</idno><idno type="eISSN">1468-3083</idno><imprint><biblScope unit="vol">27</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="789">789</biblScope><biblScope unit="page" to="792">792</biblScope><biblScope unit="page-count">4</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2013-06">2013-06</date></imprint><idno type="ISSN">0926-9959</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0926-9959</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract">Background Classic Kaposi’s sarcoma (CKS) affects an elderly population; it is important to have effective treatment options with high activity and relatively low toxicity, and availability to be used for long periods.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>etoposide</json:string><json:string>oral etoposide</json:string><json:string>toxicity</json:string><json:string>sarcoma</json:string><json:string>chemotherapy</json:string><json:string>vinblastine</json:string><json:string>venereology</json:string><json:string>dermatology</json:string><json:string>european academy</json:string><json:string>tumour</json:string><json:string>haematological</json:string><json:string>jeadv</json:string><json:string>neutropaenia</json:string><json:string>anaemia</json:string><json:string>mediterranean sarcoma</json:string><json:string>single agent</json:string><json:string>brambilla</json:string><json:string>authors journal</json:string><json:string>stable disease</json:string><json:string>oral administration</json:string><json:string>effective treatment options</json:string><json:string>elderly population</json:string><json:string>median</json:string><json:string>oral administration schedule</json:string><json:string>partial responses</json:string><json:string>small studies</json:string><json:string>febrile neutropaenia</json:string><json:string>plasma concentrations</json:string><json:string>overall survival rate</json:string><json:string>negative test</json:string><json:string>principal side effect</json:string><json:string>high activity</json:string><json:string>haematological toxicity</json:string><json:string>untreated patients</json:string><json:string>overall response rate</json:string><json:string>tumour response</json:string><json:string>second cycle</json:string><json:string>remarkable improvement</json:string><json:string>gastrointestinal toxicities</json:string><json:string>severe anaemia</json:string><json:string>regimen</json:string></teeft></keywords><author><json:item><name>F. Tas</name><affiliations><json:string>E-mail: faruktas2002@yahoo.com</json:string></affiliations></json:item><json:item><name>F. Sen</name><affiliations><json:string>Institute of Oncology, University of Istanbul, Istanbul, Turkey</json:string></affiliations></json:item><json:item><name>S. Keskin</name><affiliations><json:string>Institute of Oncology, University of Istanbul, Istanbul, Turkey</json:string></affiliations></json:item><json:item><name>L. Kilic</name><affiliations><json:string>Institute of Oncology, University of Istanbul, Istanbul, Turkey</json:string></affiliations></json:item></author><articleId><json:string>JDV4404</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>shortCommunication</json:string></originalGenre><qualityIndicators><score>4.383</score><pdfVersion>1.7</pdfVersion><pdfPageSize>595.276 x 782.362 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>219</abstractCharCount><pdfWordCount>1999</pdfWordCount><pdfCharCount>12753</pdfCharCount><pdfPageCount>4</pdfPageCount><abstractWordCount>32</abstractWordCount></qualityIndicators><title>Oral etoposide as first‐line therapy in the treatment of patients with advanced classic Kaposi’s sarcoma (CKS): a single‐arm trial (oral etoposide in CKS)</title><genre><json:string>brief-communication</json:string></genre><host><title>Journal of the European Academy of Dermatology and Venereology</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1468-3083</json:string></doi><issn><json:string>0926-9959</json:string></issn><eissn><json:string>1468-3083</json:string></eissn><publisherId><json:string>JDV</json:string></publisherId><volume>27</volume><issue>6</issue><pages><first>789</first><last>792</last><total>4</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>SHORT REPORT</value></json:item></subject></host><categories><wos><json:string>science</json:string><json:string>dermatology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>dermatology & venereal diseases</json:string></scienceMetrix></categories><publicationDate>2013</publicationDate><copyrightDate>2013</copyrightDate><doi><json:string>10.1111/j.1468-3083.2011.04404.x</json:string></doi><id>1AAFF4322434DC1B2D465784F08912917BE752C3</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/1AAFF4322434DC1B2D465784F08912917BE752C3/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/1AAFF4322434DC1B2D465784F08912917BE752C3/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/1AAFF4322434DC1B2D465784F08912917BE752C3/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Oral etoposide as first‐line therapy in the treatment of patients with advanced classic Kaposi’s sarcoma (CKS): a single‐arm trial (oral etoposide in CKS)</title></titleStmt><publicationStmt><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><licence>© 2011 The Authors. Journal of the European Academy of Dermatology and Venereology © 2011 European Academy of Dermatology and Venereology</licence></availability><date type="published" when="2013-06"></date></publicationStmt><notesStmt><note type="content-type" subtype="brief-communication" source="shortCommunication" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-S9SX2MFS-0">brief-communication</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="brief-communication"><analytic><title level="a" type="main">Oral etoposide as first‐line therapy in the treatment of patients with advanced classic Kaposi’s sarcoma (CKS): a single‐arm trial (oral etoposide in CKS)</title><title level="a" type="short">Oral etoposide in CKS</title><author xml:id="author-0000" role="corresp"><persName><forename type="first">F.</forename><surname>Tas</surname></persName><affiliation>F. Tas. E‐mail:faruktas2002@yahoo.com</affiliation></author><author xml:id="author-0001"><persName><forename type="first">F.</forename><surname>Sen</surname></persName><affiliation>Institute of Oncology, University of Istanbul, Istanbul, Turkey<address><country key="TR"></country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">S.</forename><surname>Keskin</surname></persName><affiliation>Institute of Oncology, University of Istanbul, Istanbul, Turkey<address><country key="TR"></country></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">L.</forename><surname>Kilic</surname></persName><affiliation>Institute of Oncology, University of Istanbul, Istanbul, Turkey<address><country key="TR"></country></address></affiliation></author><idno type="istex">1AAFF4322434DC1B2D465784F08912917BE752C3</idno><idno type="DOI">10.1111/j.1468-3083.2011.04404.x</idno><idno type="unit">JDV4404</idno><idno type="toTypesetVersion">file:JDV.JDV4404.pdf</idno></analytic><monogr><title level="j" type="main">Journal of the European Academy of Dermatology and Venereology</title><title level="j" type="alt">JOURNAL OF EUROPEAN ACADEMY DERMATOLOGY VENEREOLOGY</title><idno type="pISSN">0926-9959</idno><idno type="eISSN">1468-3083</idno><idno type="book-DOI">10.1111/(ISSN)1468-3083</idno><idno type="book-part-DOI">10.1111/jdv.2013.27.issue-6</idno><idno type="product">JDV</idno><idno type="publisherDivision">ST</idno><imprint><biblScope unit="vol">27</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="789">789</biblScope><biblScope unit="page" to="792">792</biblScope><biblScope unit="page-count">4</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2013-06"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><abstract xml:lang="en" style="main"><head>Abstract</head><p><hi rend="bold">Background </hi> Classic Kaposi’s sarcoma (CKS) affects an elderly population; it is important to have effective treatment options with high activity and relatively low toxicity, and availability to be used for long periods.</p><p><hi rend="bold">Objective </hi> We investigated the activity and safety of single‐agent etoposide with an oral administration schedule in patients with advanced CKS.</p><p><hi rend="bold">Methods </hi> Histologically confirmed, CKS patients were eligible for study. All had a negative test for HIV and good performance status. All patients received oral etoposide 50 mg twice daily for 10 days every 3 weeks.</p><p><hi rend="bold">Results </hi> Thirty patients (median age 66 and 22 males) were enrolled into the study. The majority of them had non‐metastatic, local advanced disease and symptoms in nearly half of patients. Complete and partial responses were observed in 10% and 77% of patients, respectively, giving an overall response rate of 87%. Stable disease occurred in the other 13% of patients. Treatment was well tolerated. Grade IV toxicity was not observed. Haematological toxicity was the principal dose‐limiting side effect. Severe leucopaenia and neutropaenia were observed in 7% and 10% of patients respectively. No patient was complicated by febrile neutropaenia. Mild‐moderate anaemia observed frequently, but only 3% of patients had severe anaemia and severe thrombocytopaenia was not observed. The 5‐year overall survival rate was 92%.</p><p><hi rend="bold">Conclusions </hi> Single‐agent oral etoposide is an effective treatment option and is acceptably toxic and easily administered. Therefore, we recommend the single agent of oral etoposide as the first‐line chemotherapy for advanced CKS.</p></abstract><textClass><classCode scheme="tocHeading1">SHORT REPORTS</classCode><classCode scheme="articleCategory">SHORT REPORT</classCode></textClass><langUsage><language ident="EN"></language></langUsage></profileDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/1AAFF4322434DC1B2D465784F08912917BE752C3/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1468-3083</doi><issn type="print">0926-9959</issn><issn type="electronic">1468-3083</issn><idGroup><id type="product" value="JDV"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="JOURNAL OF EUROPEAN ACADEMY DERMATOLOGY VENEREOLOGY">Journal of the European Academy of Dermatology and Venereology</title></titleGroup></publicationMeta><publicationMeta level="part" position="06106"><doi origin="wiley">10.1111/jdv.2013.27.issue-6</doi><numberingGroup><numbering type="journalVolume" number="27">27</numbering><numbering type="journalIssue" number="6">6</numbering></numberingGroup><coverDate startDate="2013-06">June 2013</coverDate></publicationMeta><publicationMeta level="unit" type="shortCommunication" position="19" status="forIssue"><doi origin="wiley">10.1111/j.1468-3083.2011.04404.x</doi><idGroup><id type="unit" value="JDV4404"></id></idGroup><countGroup><count type="pageTotal" number="4"></count></countGroup><titleGroup><title type="tocHeading1">SHORT REPORTS</title><title type="articleCategory">SHORT REPORT</title></titleGroup><copyright>© 2011 The Authors. Journal of the European Academy of Dermatology and Venereology © 2011 European Academy of Dermatology and Venereology</copyright><eventGroup><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:3.2.2 mode:FullText" date="2013-05-06"></event><event agent="SPS" date="2013-05-07" type="xmlCorrected"></event><event type="publishedOnlineEarlyUnpaginated" date="2011-12-20"></event><event type="firstOnline" date="2011-12-20"></event><event type="publishedOnlineFinalForm" date="2013-05-08"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-19"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.6.4 mode:FullText" date="2015-10-02"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="789">789</numbering><numbering type="pageLast" number="792">792</numbering></numberingGroup><correspondenceTo> F. Tas. <b>E‐mail:</b><email>faruktas2002@yahoo.com</email></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:JDV.JDV4404.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received: 23 October 2011; Accepted: 28 November 2011</unparsedEditorialHistory><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="3"></count></countGroup><titleGroup><title type="main">Oral etoposide as first‐line therapy in the treatment of patients with advanced classic Kaposi’s sarcoma (CKS): a single‐arm trial (oral etoposide in CKS)</title><title type="shortAuthors">Faruk <i>et al.</i></title><title type="short">Oral etoposide in CKS</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" corresponding="yes"><personName><givenNames>F.</givenNames><familyName>Tas</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#aff-1-1"><personName><givenNames>F.</givenNames><familyName>Sen</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#aff-1-1"><personName><givenNames>S.</givenNames><familyName>Keskin</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#aff-1-1"><personName><givenNames>L.</givenNames><familyName>Kilic</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="aff-1-1" countryCode="TR"><unparsedAffiliation>Institute of Oncology, University of Istanbul, Istanbul, Turkey</unparsedAffiliation></affiliation></affiliationGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p><b>Background </b> Classic Kaposi’s sarcoma (CKS) affects an elderly population; it is important to have effective treatment options with high activity and relatively low toxicity, and availability to be used for long periods.</p><p><b>Objective </b> We investigated the activity and safety of single‐agent etoposide with an oral administration schedule in patients with advanced CKS.</p><p><b>Methods </b> Histologically confirmed, CKS patients were eligible for study. All had a negative test for HIV and good performance status. All patients received oral etoposide 50 mg twice daily for 10 days every 3 weeks.</p><p><b>Results </b> Thirty patients (median age 66 and 22 males) were enrolled into the study. The majority of them had non‐metastatic, local advanced disease and symptoms in nearly half of patients. Complete and partial responses were observed in 10% and 77% of patients, respectively, giving an overall response rate of 87%. Stable disease occurred in the other 13% of patients. Treatment was well tolerated. Grade IV toxicity was not observed. Haematological toxicity was the principal dose‐limiting side effect. Severe leucopaenia and neutropaenia were observed in 7% and 10% of patients respectively. No patient was complicated by febrile neutropaenia. Mild‐moderate anaemia observed frequently, but only 3% of patients had severe anaemia and severe thrombocytopaenia was not observed. The 5‐year overall survival rate was 92%.</p><p><b>Conclusions </b> Single‐agent oral etoposide is an effective treatment option and is acceptably toxic and easily administered. Therefore, we recommend the single agent of oral etoposide as the first‐line chemotherapy for advanced CKS.</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Conflict of interest
None.</p></note><note xml:id="fn2"><p>Funding sources
None.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Oral etoposide as first‐line therapy in the treatment of patients with advanced classic Kaposi’s sarcoma (CKS): a single‐arm trial (oral etoposide in CKS)</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Oral etoposide in CKS</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Oral etoposide as first‐line therapy in the treatment of patients with advanced classic Kaposi’s sarcoma (CKS): a single‐arm trial (oral etoposide in CKS)</title></titleInfo><name type="personal"><namePart type="given">F.</namePart><namePart type="family">Tas</namePart><affiliation>E-mail: faruktas2002@yahoo.com</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">F.</namePart><namePart type="family">Sen</namePart><affiliation>Institute of Oncology, University of Istanbul, Istanbul, Turkey</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S.</namePart><namePart type="family">Keskin</namePart><affiliation>Institute of Oncology, University of Istanbul, Istanbul, Turkey</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L.</namePart><namePart type="family">Kilic</namePart><affiliation>Institute of Oncology, University of Istanbul, Istanbul, Turkey</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="brief-communication" displayLabel="shortCommunication"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">2013-06</dateIssued><edition>Received: 23 October 2011; Accepted: 28 November 2011</edition><copyrightDate encoding="w3cdtf">2013</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">3</extent></physicalDescription><abstract>Background Classic Kaposi’s sarcoma (CKS) affects an elderly population; it is important to have effective treatment options with high activity and relatively low toxicity, and availability to be used for long periods.</abstract><abstract>Objective We investigated the activity and safety of single‐agent etoposide with an oral administration schedule in patients with advanced CKS.</abstract><abstract>Methods Histologically confirmed, CKS patients were eligible for study. All had a negative test for HIV and good performance status. All patients received oral etoposide 50 mg twice daily for 10 days every 3 weeks.</abstract><abstract>Results Thirty patients (median age 66 and 22 males) were enrolled into the study. The majority of them had non‐metastatic, local advanced disease and symptoms in nearly half of patients. Complete and partial responses were observed in 10% and 77% of patients, respectively, giving an overall response rate of 87%. Stable disease occurred in the other 13% of patients. Treatment was well tolerated. Grade IV toxicity was not observed. Haematological toxicity was the principal dose‐limiting side effect. Severe leucopaenia and neutropaenia were observed in 7% and 10% of patients respectively. No patient was complicated by febrile neutropaenia. Mild‐moderate anaemia observed frequently, but only 3% of patients had severe anaemia and severe thrombocytopaenia was not observed. The 5‐year overall survival rate was 92%.</abstract><abstract>Conclusions Single‐agent oral etoposide is an effective treatment option and is acceptably toxic and easily administered. Therefore, we recommend the single agent of oral etoposide as the first‐line chemotherapy for advanced CKS.</abstract><relatedItem type="host"><titleInfo><title>Journal of the European Academy of Dermatology and Venereology</title></titleInfo><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>SHORT REPORT</topic></subject><identifier type="ISSN">0926-9959</identifier><identifier type="eISSN">1468-3083</identifier><identifier type="DOI">10.1111/(ISSN)1468-3083</identifier><identifier type="PublisherID">JDV</identifier><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>27</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>789</start><end>792</end><total>4</total></extent></part></relatedItem><identifier type="istex">1AAFF4322434DC1B2D465784F08912917BE752C3</identifier><identifier type="DOI">10.1111/j.1468-3083.2011.04404.x</identifier><identifier type="ArticleID">JDV4404</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2011 The Authors. Journal of the European Academy of Dermatology and Venereology © 2011 European Academy of Dermatology and Venereology</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C45 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000C45 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:1AAFF4322434DC1B2D465784F08912917BE752C3
|texte= Oral etoposide as first‐line therapy in the treatment of patients with advanced classic Kaposi’s sarcoma (CKS): a single‐arm trial (oral etoposide in CKS)
}}
| This area was generated with Dilib version V0.6.31. |  |